Sunshine Biopharma, Inc. (SBFM)

Sunshine Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	16.29	21.83	2.05	1	0.05
Cash & Cash Equivalents	16.29	21.83	2.05	1	0.05
Cash Growth	-25.35%	963.27%	105.79%	1974.15%	-56.49%
Receivables	2.55	1.91	0.01	0	0
Inventory	5.73	3.29	0.11	0.02	0.02
Other Current Assets	0.31	0.28	0.03	0	0
Total Current Assets	24.89	27.31	2.2	1.03	0.07
Property, Plant & Equipment	1.01	1.15	0.01	0.02	0.03
Goodwill and Intangibles	1.44	0.78	0	0	0
Total Long-Term Assets	2.46	1.93	0.01	0.02	0.03
Total Assets	27.35	29.24	2.2	1.05	0.1
Accounts Payable	5.13	6.43	0.04	0.06	0.1
Current Debt	0.12	0.12	0	0.96	0.72
Other Current Liabilities	0.3	0.37	0.05	0.02	0.02
Total Current Liabilities	5.55	6.93	0.09	1.05	0.83
Long-Term Debt	0.54	0.64	1.9	0.95	0
Other Long-Term Liabilities	0.05	0.04	0	0	0
Total Long-Term Liabilities	0.59	0.69	1.9	0.95	0
Total Liabilities	6.14	7.62	1.99	2	0.83
Total Debt	0.66	0.77	1.9	1.91	0.72
Debt Growth	-14.05%	-59.72%	-0.69%	167.36%	4.67%
Retained Earnings	-63.91	-59.4	-32.66	-20.22	-17.43
Comprehensive Income	0.7	0.16	-0.02	-0	-0
Shareholders' Equity	21.21	21.63	0.21	-0.95	-0.74
Net Cash / Debt	15.63	21.06	0.15	-0.92	-0.67
Net Cash / Debt Growth	-25.77%	13687.37%	-	-	-
Net Cash Per Share	64.26	138.73	5.85	-89.72	-1220.25
Working Capital	19.34	20.38	2.1	-0.03	-0.77
Book Value Per Share	87.16	142.47	8.10	-93.57	-1345.28

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).